Payne SJ, Stebbing J, Wilson P, Slater S (2011) Outcomes in unresectable and locally advanced resected cholangiocarcinoma. Expert Rev Anticancer Ther, 11(5):705-709
Table 1
The overall survival of patients with unresectable or locally advanced resected biliary tract cancer (Gall bladder cancer, cholangiocarcinoma, ampullar cancer) who received Gemcitabine as a single agent (primary chemotherapy or relapse disease) is 2.9 months.
Table 1
The overall survival of patients with unresectable or locally advanced resected biliary tract cancer (Gall bladder cancer, cholangiocarcinoma, ampullar cancer) who received Gemcitabine as a single agent (primary chemotherapy or relapse disease) is 2.9 months.
No comments:
Post a Comment